ELDERPHARM

Elder Pharmaceuticals Limited has informed the Exchange, vide letter dated March 11, 2015 regarding an announcement titled "Elder Pharmaceuticals Limited completes making statutory payments".

Elder Pharmaceuticals Limited has informed the Exchange vide letter dated June 29, 2014 regarding "Elder Pharmaceuticals limited completes the sale of domestic branded formulations business with Torrent Pharmaceuticals limited".

Elder Pharmaceuticals Limited has informed the Exchange that NutraHealth Ltd. (a wholly owned step down subsidiary of Elder Pharmaceuticals Ltd. of Mumbai, India), the UK's leading provider of the highest quality and innovative branded and own label vitamin and food supplements, has acquired Max Healthcare Ltd. to re-enter the OTC pharmaceutical category and extend and enhance its product range. Max Healthcare is an OTC business which owns a range of marketing authorisations and provides own label and branded OTC medicines and products to a broad range of customers. Max Healthcare will be a su

Elder Pharmaceuticals Limited has informed the Exchange that : "Ratnakar Bank Ltd. have invoked pledge of our Company's shares and have on 10th and 11th instants sold some of them in the market. This has affected the market price of the shares and the volume also has increased. However, kindly note that neither the promoters nor persons acting in concert have sold any shares in the market".

Elder Pharmaceuticals Limited has informed the Exchange that: "On 10th and 11th instants Ratnakar Bank Ltd. have sold shares of our Company in the market because of which the market price of the shares has come down and volume also has increased. However, kindly note that neither the promoters nor persons acting in concert have sold any shares in the market".

Elder Pharmaceuticals Limited has informed the Exchange that there was fluctuation in Company's share price on March 06, 2012 and March 07, 2012. There was an Income Tax Search u/s 132 of Income Tax Act, 1961 on various premises of the Company. However, the said search has hardly yielded anything against the Company.

Elder Pharmaceuticals Limited has informed the Exchange that on February 07, 2012, the Company through its Dubai wholly owned subsidiary has increased the stake in Elder Biomeda AD, Bulgaria from existing 92.2% to 100%.

Elder Pharmaceuticals Limited has informed the Exchange that the Company's Whole Time Director, Mr. Alok Saxena is giving an interview on the 'CNBC', TV channel with regards to the Company on June 07, 2011.

Elder Pharmaceuticals Limited has informed the Exchange that the scheme of arrangement has become effective from November 16, 2010 and accordingly acquisition of NutraHealth Plc, U.K. had been completed.

Elder Pharmaceuticals Limited has informed the Exchange that the Court Convened Meeting was held on October 25, 2010 to approve the scheme of arrangement. The scheme was approved by requisite number of votes. The General Meeting of NeutraHealth plc was also held on October 25, 2010 to implement the scheme of arrangement. All the resolutions in order to approve and implement the Scheme received the requisite number of votes and were accordingly approved.

Elder Pharmaceuticals Limited had informed the Exchange regarding the announcement made for the proposed takeover of an AIM listed Company in the U. K. by way of a Scheme of Arrangement. The Company has now informed the Exchange that the Scheme Document has been/is being posted on October 01, 2010 to the shareholders of the Target Company, viz NeutraHealth PLC.

Elder Pharmaceuticals Limited has submitted to the Exchange a brief summary of the comparative financial results for the year ended on March 31, 2008 and March 31, 2010.

Elder Pharmaceuticals Limited has informed the Exchange that commercial activities have been commenced in Elder Bulgaria EOOD, the subsidiary of the step-down subsidiary of the Company in Bulgaria. Elder Bulgaria EOOD is engaged in distribution business in Bulgaria.

Elder Pharmaceuticals Limited has submitted to the Exchange a brief summary of the comparative financial results for the year ended on March 31, 2008 and March 31, 2009. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ELDER_UPDATES_25082009.zip target=NEW> For more details click here.</a>

Elder Pharmaceuticals Limited had informed the Exchange about the unsolicited approach made by wholly owned subsidiary of the Company to NeutraHealth plc, UK for the possible partial offer at an indicative offer price of 5.5p per share which could result in the subsidiary's shareholding increasing from existing 21% to between 50 and 60%. The Company has now informed the Exchange that the said offer has since been terminated.

Elder Pharmaceuticals Limited has informed the Exchange that "The Wholly owned Dubai subsidiary of the Company has made an unsolicited approach NeutraHealth Plc, UK, in which it has 21% stake. The approach may or may not lead to a partial offer that would result in the subsidiary�s shareholding increasing from 21% to between 50 and 60%. The indicative partial offer price is at or around 5.5p per share".

Elder Pharmaceuticals Limited has informed the Exchange that "The Company has entered into an agreement with M/s Daiwa Pharmaceuticals Co. Ltd. of Japan for manufacturing and marketing of some of their products in India. M/s. Daiwa Pharmaceuticals specializes in health supplements and functional foods and their products are well accepted in more than 42 countries. We propose to initially launch in the Indian market "IMBRAN", a novel nutritional supplement for immunity enhancement".

Elder Pharmaceuticals Limited has submitted to the Exchange the brief summary of the comparative financial results for the years ended on March 31, 2008 and March 31, 2007. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Elder_26082008.zip target=NEW> For more details click here.</a>

Elder Pharmaceuticals Limited had informed the Exchange that the Company was seeking to raise funds through an issue of Foreign Currency Convertible Bonds/GDRs to the extent of US Dollars 50 million. The Company has now informed the Exchange that: "Our Company had in August 2007 engaged the Royal Bank of Scotland Plc and ICICI Bank to act as Placement Agents for a proposed offering of Foreign Currency Convertible Bonds (FCCBs) upto an amount of US Dollar 30 million which were required to be listed on the Singapore Stock Exchange. In pursuance of the engagement of the Placement Agents, our Com